• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Kamada Announces US$25 Million Private Placement

    Danielle Edwards
    Jan. 21, 2020 08:44AM PST
    Pharmaceutical Investing

    Kamada has entered a purchase agreement with FIMI Opportunity Funds to purchase US$25 million of its ordinary shares in a private placement.

    Kamada (NASDAQ:KMDA,TASE:KMDA) has entered into a securities purchase agreement with Israeli FIMI Opportunity Funds (FIMI) to purchase US$25 million of its ordinary shares in a private placement.

    As quoted on the press release:

    No placement agent fees will be incurred by the Company in connection with the transaction.

    Under the terms of the agreement, Kamada will issue an aggregate of 4,166,667 ordinary shares to FIMI at a price of $6.00 per share (which represents a discount of approximately eight percent to the closing price of the Company’s shares on NASDAQ on January 17, 2020, and a discount of approximately 5.5% to the last three months average closing price of the Company’s shares on NASDAQ). Upon the closing of the transaction, FIMI will beneficially own approximately 21% of Kamada’s outstanding ordinary shares.

    Click here to read the full press release.

    pharmaceutical investingkamadatase:kmdanasdaq:kmda
    The Conversation (0)

    Go Deeper

    AI Powered
    InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

    InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

    Sarama Announces Equity Placement of Up to A$2M and Issue of Equity for Debt

    Sarama Announces Equity Placement of Up to A$2M and Issue of Equity for Debt

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×